MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it entered into a debt facility of up to $90 million with Perceptive Advisors LLC (Perceptive). Under the term loan, Neuronetics received the first tranche of $50 million at closing. Part of the initial $50 million tranche will be used to ...

MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release second quarter 2024 financial and operating results prior to market open on Monday, August 12th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. Neuronetics, Inc. b ...

The coverage criteria specify that TMS treatment must be administered by an FDA-cleared device in accordance with FDA labeled indications. Aetna is one of the largest health plans in the country with over 19.4 million lives covered through its commercial policies nationwide. The TMS policy update is effective immediately. For more information about NeuroStar TMS Therapy, please visit www.neurostar.com. About Neuronetics MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medic ...

Medi-Cal is California's Medicaid healthcare program. It offers no-cost and low-cost health coverage for children and adults with limited income and resources who meet eligibility requirements. Medi-Cal policies impact 14.8 million covered lives in California. The TMS policy update will go into effect on August 1, 2024. "At a time when mental health services are more essential than ever, expanded access to NeuroStar TMS through Medi-Cal is a pivotal step in addressing the growing need for care among both ad ...

Medi-Cal is California's Medicaid healthcare program. It offers no-cost and low-cost health coverage for children and adults with limited income and resources who meet eligibility requirements. Medi-Cal policies impact 14.8 million covered lives in California. The TMS policy update will go into effect on August 1, 2024. Neuronetics is the first and only TMS company with FDA clearance for the treatment of adolescents and the only company in the industry with a dedicated health policy team that partners with ...

BCBS Michigan covers 4.9 million lives in the state of Michigan, and the policy includes TMS access for members 15-70 years of age. Cambia Health Solutions is the parent company of Regence BCBS, Asuris Health, and BridgeSpan Health, which covers 2.5 million lives throughout the states of Washington, Utah, Oregon, and Idaho. The policy allows TMS eligibility for ages consistent with device-specific FDA indication. The effective date for both policies is September 1, 2024. For more information about NeuroStar ...

BCBS Michigan covers 4.9 million lives in the state of Michigan, and the policy includes TMS access for members 15-70 years of age. Cambia Health Solutions is the parent company of Regence BCBS, Asuris Health, and BridgeSpan Health, which covers 2.5 million lives throughout the states of Washington, Utah, Oregon, and Idaho. The policy allows TMS eligibility for ages consistent with device-specific FDA indication. The effective date for both policies is September 1, 2024. BCBS of Michigan and Cambia's Regenc ...

Better Me Provider Program is an extensive commercial initiative to support practices committed to meeting patient care and responsiveness standards. These standards are developed in collaboration with TMS medical experts, ensuring prompt response times by a dedicated NeuroStar coordinator, who advises patients about the benefits of the entire course of NeuroStar treatment, along with optimizing websites and social media content to educate patients. It is designed to help people with major depressive disord ...

文章核心观点 - 公司推出了"Better Me Provider (BMP)"计划,旨在提高精神健康行业的患者护理和响应能力,为患者提供更优质的治疗体验 [1][2][5] - 该计划在试运行阶段取得了显著成功,包括大幅提高了响应时间、提升了医生的培训水平、加快了患者的参与过程 [2][3][4] - 该计划现已全国推出,目前已有300家活跃网点参与,未来还将有更多网点加入 [6][7] 公司概况 - 公司专注于设计、开发和销售改善患者神经健康障碍生活质量的产品 [1] - 公司的主要产品是NeuroStar先进治疗系统,是目前治疗成人抑郁症的主要经颅磁刺激(TMS)疗法,已经完成了超过640万次治疗 [11] - 该系统还获得FDA批准用于治疗强迫症和15-21岁青少年抑郁症 [11] 计划详情 - "Better Me Provider"计划是公司与TMS医疗专家合作制定的一项全面的商业计划 [7] - 参与该计划的医疗机构需满足一系列严格的患者护理和响应标准,包括仅使用NeuroStar系统、参加NeuroStar培训、确保快速响应时间等 [7] - 该计划旨在提高患者的治疗可及性,让更多需要帮助的人获得潜在的生命改变性治疗 [2]

文章核心观点 公司推出了"Better Me Provider"(BMP)计划,旨在提高精神健康行业的患者护理和响应能力,为患者提供更优质的治疗体验 [1][2][5] 关于BMP计划 1) BMP计划是一项全面的商业计划,与TMS医疗专家合作制定了严格的标准,包括:专门使用NeuroStar治疗、参加NeuroStar University培训、确保及时响应、建议患者完成全程治疗、优化网站和社交媒体内容等 [7] 2) 在试点阶段,BMP计划显示了显著成功,大幅提高了提供者的效率和响应能力,从而改善了NeuroStar患者的体验 [2] 3) 参与BMP计划的诊所将获得公司的支持,帮助他们满足入选标准并加入该计划 [6] 患者体验改善 1) 参与BMP计划的诊所将响应时间提高了6.4倍,大幅缩短了从初次咨询到运动阈值测定的时间,使得3.6倍更多的患者接受了治疗 [2][4] 2) 通过NeuroStar University的高级培训,参与者平均能治疗58%更多的患者 [3] 公司概况 1) 公司致力于设计、开发和销售改善患者生活质量的神经健康产品,其NeuroStar高级治疗是目前治疗成人抑郁症的主要TMS疗法 [11] 2) NeuroStar治疗可以改善抑郁症和焦虑症状,并获批用于治疗强迫症和青少年抑郁症 [11]